Avacopan Phase 1 Study Results
Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small-Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody-Associated Vascultis.
Shichang Milao, Pablo Suso, John A. Furst, Matthew G Hudson, Ashit Trivedi
First Published 11 July 2024 | https://doi.org/10.1002/cpdd.1444
- This article provides details showing the effect of hepatic impairment on the pharmacokinetics of avacopan capsules for oral use. Prosoft provided full service support for the conduct, analysis, and report writing for this Phase 1 clinical study.
- It was recently included in the July 2024 edition of Clinical Pharmacology in Drug Development, released by the American College of Clinical Pharmacology.
- Please consider Prosoft Clinical for your full-service Phase 1 clinical study needs!